Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-12-08 2:11 pm Purchase | 13D | ADDEX THERAPEUTICS LTD ADS ADXN | Growth Equity Opportunities Fund IV LLC | 7,704,600 6.4% | 7,704,600 (New Position) | View |
| 2023-11-29 4:00 pm Purchase | 13D | ADDEX THERAPEUTICS LTD ADS ADXN | Dyer Timothy Mark | 16,863,355 14.16% | 16,863,355 (New Position) | View |
| 2023-04-10 4:06 pm Unchanged | 13D | ADDEX THERAPEUTICS LTD ADS ADXN | Growth Equity Opportunities Fund IV LLC | 7,704,600 8.5% | 0 (Unchanged) | View |
| 2023-04-05 4:00 pm Unchanged | 13D | ADDEX THERAPEUTICS LTD ADS ADXN | Dyer Timothy Mark | 9,855,322 11.09% | 0 (Unchanged) | View |
| 2023-03-31 4:00 pm Unchanged | 13D | ADDEX THERAPEUTICS LTD ADS ADXN | Dyer Timothy Mark | 9,855,322 12.18% | 0 (Unchanged) | View |
| 2023-02-16 2:49 pm Sale | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | ARMISTICE CAPITAL LLC | 675,295 4.99% | -3,363,167 (-83.28%) | View |
| 2023-02-14 12:30 pm Sale | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | CAXTON CORP | 718,849 0.9% | -1,595,640 (-68.94%) | View |
| 2023-02-14 11:53 am Purchase | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | ARMISTICE CAPITAL LLC | 4,038,462 4.97% | 3,405,665 (+538.19%) | View |
| 2023-02-07 6:08 pm Sale | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | GOLDMAN SACHS GROUP INC GS | 2,063 0% | -3,004,919 (-99.93%) | View |
| 2023-02-06 4:32 pm Sale | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | New Leaf Biopharma Opportunities I L.P. | 2,316,293 3% | -50,000 (-2.11%) | View |
| 2022-11-28 3:19 pm Unchanged | 13D | ADDEX THERAPEUTICS LTD ADS ADXN | Growth Equity Opportunities Fund IV LLC | 7,704,600 9.7% | 0 (Unchanged) | View |
| 2022-11-23 06:00 am Unchanged | 13D | ADDEX THERAPEUTICS LTD ADS ADXN | Dyer Timothy Mark | 9,855,322 13.54% | 0 (Unchanged) | View |
| 2022-11-09 4:00 pm Purchase | 13D | ADDEX THERAPEUTICS LTD ADS ADXN | Dyer Timothy Mark | 9,855,322 20.01% | 5,394,822 (+120.95%) | View |
| 2022-08-23 5:18 pm Unchanged | 13D | ADDEX THERAPEUTICS LTD ADS ADXN | Growth Equity Opportunities Fund IV LLC | 7,704,600 15.1% | 0 (Unchanged) | View |
| 2022-08-05 06:01 am Purchase | 13D | ADDEX THERAPEUTICS LTD ADS ADXN | Dyer Timothy Mark | 4,460,500 8.4% | 829,512 (+22.85%) | View |
| 2022-02-18 4:54 pm Unchanged | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | New Leaf Biopharma Opportunities I L.P. | 2,366,293 6.2% | 0 (Unchanged) | View |
| 2022-02-14 6:33 pm Purchase | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | ARMISTICE CAPITAL LLC | 632,797 9.99% | 632,797 (New Position) | View |
| 2022-02-14 4:07 pm Sale | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | CAXTON CORP | 2,314,489 6% | -1,804 (-0.08%) | View |
| 2022-02-14 3:32 pm Purchase | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | GOLDMAN SACHS GROUP INC GS | 3,006,982 6.1% | 3,006,982 (New Position) | View |
| 2022-02-14 1:57 pm Purchase | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | CREDIT SUISSE AG | 1,876,604 4.95% | 2,359 (+0.13%) | View |